Ascendis Pharma A/S (BVMF:A1SN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
70.21
-1.26 (-1.76%)
At close: Nov 4, 2025
45.06%
Market Cap 67.53B
Revenue (ttm) 4.04B
Net Income (ttm) -1.46B
Shares Out n/a
EPS (ttm) -24.19
PE Ratio n/a
Forward PE 75.15
Dividend n/a
Ex-Dividend Date n/a
Volume 10
Average Volume 235
Open 70.21
Previous Close 71.47
Day's Range 70.21 - 70.21
52-Week Range 48.60 - 76.48
Beta 0.45
RSI 55.70
Earnings Date Feb 11, 2026

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 1,017
Stock Exchange Brazil Stock Exchange
Ticker Symbol A1SN34
Full Company Profile

Financial Performance

In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.

Financial numbers in EUR Financial Statements

News

There is no news available yet.